Forgot Password?
Return to Course Listing

CME: Metastatic Melanoma: Novel Approaches in Immuno- and Molecularly- Targeted Therapy, Therapeutic Updates, and Best Practices in Involving the Patient in Care

Activity Description / Statement of Need:

Melanoma is a tumor of the melanocytes whose tissue of origin is primarily the skin, although it may also develop occasionally in the: gastrointestinal, genitourinary, or respiratory tracts; ocular or mucosal tissue; or meninges. It is subcategorized into superficial spreading melanoma (70% of cases), nodular melanoma (15-30%), lentigo maligna melanoma (10%-20%), and acral lentiginous melanoma (5%). Risk factors include a positive personal or family history of melanoma, genetic predisposition, and exposure to ultraviolet light.Diagnosis is made by excisional, incisional, or punch skin biopsy while imaging or indirect ophthalmoscopy may be employed to diagnose uveal or choroidal melanoma.The seventh most common cancer in the U.S., it has an annual incidence of over 76,000.

 

In this online CME self-learning program:

 

Faculty introduction, disclosures

Introduction content: cursory refresher and review

  • Epidemiology: statistics by severity
  • Causes and risk factors
  • Clinical features, presentation, and histopathology
  • Pathogenesis and the role of the immune system

Emerging immuno- and monoclonal therapy in melanoma

  • How has the treatment landscape changed in the last decade, and where is it going?
  • Immunotherapy and monoclonal antibodies vs. conventional cytotoxic chemotherapy: mechanisms of action and impact on biochemical pathways and the cell life cycle
  • Targeted mechanisms of action: which are the targets?
  • Safety profiles: immunotherapy and monoclonal antibodies vs. conventional cytotoxic chemotherapy
  • Other emerging therapies
  • Updates in the recent clinical literature
  • Immunotherapy and monoclonal antibodies in present melanoma treatment guidelines
  • Evaluation of therapeutic outcomes and strategies for involving and educating the patient
  • Barriers to care
  • Best practice: putting it all together
  • Patient case(s)

Summary, conclusions, and best practice recap

Target Audience:

The following healthcare professionals: oncologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with malignant melanoma.


This program is supported by educational grants from Prometheus.


Release Date: December 04, 2017 -- Expiration Date: December 04, 2019

Faculty: Diwakar Davar , MD

Agenda

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
  • Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
  • Describe emerging (investigational) therapies for metastatic melanoma
  • Describe the challenges and barriers to care associated with treating patients with metastatic melanoma

Accreditation

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

 

Faculty Disclosure:  Diwakar Davar, MD, Assistant Professor, Melanoma and Phase I Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, PA has received grants and/or serves as a consultant to Merck and Incyte Pharmaceuticals.

 

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME has no relevant financial disclosures.

 

Commercial Support Disclosure: This program is supported by educational grants from Prometheus.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Take the post-test
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Basal Cell Carcinoma (BCC): Therapeutic Updates, Best Practices, and the Role of Personalized Patient Care

Metastatic Melanoma: Updates from ASCO 2017